FDA Fast Track designation granted for Telix's BiPASS® program, which is evaluating 68Ga-PSMA-PET imaging alongside MRI in the pre-biopsy prostate cancer setting.The designation recognizes the program's potential to address an important unmet need by enabling an imaging-first approach to initial prostate cancer diagnosis.Fast Track facilitates more frequent engagement with the FDA and may enable expedited review of the planned NDA.MELBOURNE, Australia and INDIANAPOLIS, Sept. 30, 2026 /PRNewswire/ -- Telix ...